文献速递妇科

托泊替康、紫杉醇和贝伐珠单抗联合方案改善复发性宫颈小细胞神经内分泌癌的无进展生存期

Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in recurrent small cell neuroendocrine carcinoma of the cervix.
PubMed 文献 · Gynecol Oncol · 2016-11-04

该回顾性分析纳入复发性宫颈小细胞神经内分泌癌(SCCC)患者,比较一线化疗采用托泊替康+紫杉醇+贝伐珠单抗(TPB)方案(13例)与非TPB化疗(21例)的生存结局。TPB组中位无进展生存期(PFS)为7.8个月,非TPB组为4.0个月(HR 0.21,95%CI 0.09-0.54,P=0.001);中位总生存期(OS)分别为9.7个月和9.4个月(HR 0.53,95%CI 0.23-1.22,P=0.13)。作者认为TPB显著改善PFS,OS有改善趋势,且部分患者获得持久临床获益。

要点

  • TPB组中位PFS 7.8个月 vs 非TPB组4.0个月(HR 0.21,95%CI 0.09-0.54,P=0.001)。
  • TPB组中位OS 9.7个月 vs 非TPB组9.4个月(HR 0.53,95%CI 0.23-1.22,P=0.13),未达统计学显著。
  • TPB组治疗超过6个月者8例(62%) vs 非TPB组4例(19%)(P=0.02)。

核心结论

  • 作者认为,TPB方案用于复发性SCCC较非TPB方案显著改善PFS,OS有改善趋势,且相当数量患者获得持久临床获益。

研究设计与样本

  • 回顾性分析接受化疗作为主要治疗的复发性SCCC女性,将首次复发接受TPB方案者与接受非TPB化疗者进行比较;TPB组13例,非TPB组21例,后者最常用含铂方案联合或不联合紫杉类。

主要发现

  • TPB组中位PFS为7.8个月,非TPB组为4.0个月(HR 0.21,95%CI 0.09-0.54,P=0.001)。
  • TPB组中位OS为9.7个月,非TPB组为9.4个月(HR 0.53,95%CI 0.23-1.22,P=0.13)。
  • TPB组治疗超过6个月者8例(62%),非TPB组4例(19%)(P=0.02);治疗超过12个月者TPB组4例(31%),非TPB组2例(10%)(P=0.17)。
  • TPB组中,完全缓解3例(23%),脑外完全缓解但脑内进展2例(15%),部分缓解3例(23%),疾病稳定2例(15%),疾病进展3例(23%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess if the combination of topotecan, paclitaxel, and bevacizumab (TPB) was active in recurrent SCCC and to compare the survival of patients with SCCC who received TPB to a group of women with SCCC who did not receive this regimen. METHODS: We retrospectively analyzed women with recurrent SCCC who received chemotherapy as primary therapy. Women treated with TPB for first recurrence were compared to women treated with non-TPB chemotherapy. RESULTS: Thirteen patients received TPB, and 21 received non-TPB chemotherapy, most commonly platinum with or without a taxane. Median progression-free survival (PFS) was 7.8months for TPB and 4.0months for non-TPB regimens (hazard ratio [HR] 0.21, 95% CI 0.09-0.54, P=0.001). Median overall survival (OS) was 9.7months for TPB and 9.4months for non-TPB regimens (HR 0.53, 95% CI 0.23-1.22, P=0.13). Eight women (62%) who received TPB versus four (19%) who received non-TPB regimens were on treatment for >6months (P=0.02), and four patients (31%) in the TPB group versus two (10%) in the non-TPB group were on treatment for >12months (P=0.17). In the TPB group, three patients (23%) had complete response, two (15%) had complete response outside the brain with progression in the brain, 3 (23%) had a partial response, 2 (15%) had stable disease, and 3 (23%) had progressive disease. CONCLUSIONS: These findings indicate that TPB for recurrent SCCC significantly improved PFS over non-TPB regimens, and trends towards improved OS. Furthermore, a significant number of patients had a durable clinical benefit.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Frumovitz M, Munsell MF, Burzawa JK, et al. Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in recurrent small cell neuroendocrine carcinoma of the cervix. Gynecol Oncol. 2016. PMID: 27823771. doi:10.1016/j.ygyno.2016.10.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。